Nov 11, 2008 by Brian Orelli, PhDTwo Years of RedAesthetic laser makers have been rocked over the last few years.
Nov 10, 2008 by Brian Orelli, PhDDrug Fuels an Idling Rocket ShipAstraZeneca needs another FDA approval to really take advantage of cholesterol drug's success.
Nov 7, 2008 by Brian Orelli, PhDWill Obama Make Your Portfolio Healthy?The change a-comin' in the health-care industry could be a mixed bag of good and bad.
Nov 7, 2008 by Brian Orelli, PhDOnyx -- Still WaitingThe drugmaker made a positive move, but seems to be guiding lower.
Nov 7, 2008 by Brian Orelli, PhDinVentiv Reinvents GrowthNow it just needs to get a hold of expenses.
Nov 6, 2008 by Brian Orelli, PhDMaking Money by Saving MoneyMedco has a recipe for success in hard economic times.
Nov 5, 2008 by Brian Orelli, PhDZymoGenetics Leads With Its ChinWhat does it tell us when talk about a drug still in development takes top billing over sales of an approved drug?
Nov 4, 2008 by Brian Orelli, PhDDoes the Supreme Court Control Your Investment?The Supreme Court is about to make a decision that could affect drug company investors.
Nov 3, 2008 by Brian Orelli, PhDQuality Growth From Quality SystemsToo bad the bottom line couldn't keep up.
Oct 31, 2008 by Brian Orelli, PhDWorld's Scariest Stock: DendreonA volatile biotech with nowhere to go.
Oct 31, 2008 by Brian Orelli, PhDDisease Is Good for Novo NordiskThe Danish drugmaker is able to grow despite the headwind.
Oct 31, 2008 by Brian Orelli, PhDFrom Precious to PrecociousNatus Medical may make some acquisitions to continue boosting its revenue.
Oct 31, 2008 by Brian Orelli, PhDWill These Delayed Drugs Make It to Market?The FDA is taking its own sweet time.
Oct 30, 2008 by Brian Orelli, PhDNot What the Doctor OrderedBiogen reports a third case of a deadly brain disorder.
